SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-20-002153
Filing Date
2020-02-25
Accepted
2020-02-25 08:21:12
Documents
16
Period of Report
2020-02-25
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K form8-kearningsrelease.htm   iXBRL 8-K 47867
2 EXHIBIT 99.1 exhibit991-q42019.htm EX-99.1 136651
8 miratilogo2019.jpg GRAPHIC 11133
  Complete submission text file 0001628280-20-002153.txt   341009

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20200225.xsd EX-101.SCH 4564
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20200225_cal.xml EX-101.CAL 608
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20200225_def.xml EX-101.DEF 1458
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20200225_lab.xml EX-101.LAB 23061
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20200225_pre.xml EX-101.PRE 12040
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-kearningsrelease_htm.xml XML 3753
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 20647453
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences